US House and Senate committee leaders have finally come to an agreement on user fee reauthorization, just days ahead of when the current package will expire. The hitch: The deal isn’t expected to include some elements that the medtech industry had lobbied for, such as additional diagnostic oversight for the Food and Drug Administration.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?